Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why
by Amy Steele · The Cerbat GemInventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $4.84, but opened at $4.63. Inventiva shares last traded at $4.65, with a volume of 161,983 shares.
Analysts Set New Price Targets
Several analysts have recently weighed in on IVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald began coverage on shares of Inventiva in a research report on Friday, July 17th. They issued an “overweight” rating on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $15.38.
Get Our Latest Analysis on Inventiva
Inventiva Price Performance
The company’s 50 day simple moving average is $4.48 and its two-hundred day simple moving average is $5.03.
Institutional Trading of Inventiva
Several large investors have recently made changes to their positions in the stock. Creative Planning acquired a new position in shares of Inventiva during the 2nd quarter valued at about $32,000. Millennium Management LLC bought a new stake in Inventiva during the third quarter worth approximately $649,000. NewEdge Advisors LLC acquired a new position in Inventiva during the third quarter valued at approximately $116,000. UBS Group AG grew its holdings in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new position in shares of Inventiva in the fourth quarter valued at approximately $1,570,000. Institutional investors own 19.06% of the company’s stock.
About Inventiva
Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.